CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial

Ähnliche Einträge

• Younger age at initiation of subcutaneous treprostinil is associated with better response in pediatric Group 1 pulmonary arterial hypertension
  von: Justin J. Kochanski, et al.
  Veröffentlicht: (2024)
• PPARγ/ETV2 axis regulates endothelial‐to‐mesenchymal transition in pulmonary hypertension
  von: Dong Hun Lee, et al.
  Veröffentlicht: (2024)
• Structured evaluation of unclear dyspnea–An attempt to shorten the diagnostic delay in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
  von: Salaheldin Ahmed, et al.
  Veröffentlicht: (2024)
• Severe pulmonary hypertension due to combined pulmonary fibrosis and emphysema: another cause of death among smokers
  von: André Carramenha de Góes Hirano
  Veröffentlicht: (2017)
• The effects of oxygenation on acute vasodilator challenge in pulmonary arterial hypertension
  von: Matthew D. Rockstrom, et al.
  Veröffentlicht: (2024)